TITOMIC
1.7.2020 09:32:08 CEST | Business Wire | Press release
The inaugural CEO of Saudi Arabian Military Industries (SAMI), Dr Andreas Schwer, has been appointed Chairman of the Melbourne-based industrial-scale additive manufacturing company Titomic (ASX:TTT) www.titomic.com .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200701005306/en/
Beginning immediately, Dr Schwer, who boasts a 25-year career in the global defence, manufacturing, and aerospace industries will bring a wealth of experience to Titomic. The news comes just days after Titomic announced the appointments of Mr Dag W.R. Stromme, a former Managing Director of Morgan Stanley; and Mr Humphrey Nolan, an experienced leader in the global industrial and distribution industries.
As the first CEO at SAMI, which was established in 2017, Dr Schwer led this greenfield operation to become a multi-billion-dollar company in 2020 before recently stepping down.
Prior to his role at SAMI, Dr Schwer was Chairman and President of Rheinmetall International - Rheinmetall AG. Dr Schwer also held roles including CEO of Combat Systems & Executive Board Member of Rheinmetall Defence overseeing the units of Combat Platforms, Weapons & Munitions, Protection Systems, and Propulsion Systems. Dr Schwer also holds 12 years’ experience at Airbus in executive roles across the Defence & Space and Helicopter divisions.
Titomic’s Managing Director and Founder, Mr. Jeff Lang, said: “Andreas’ extensive professional experience in the global defence and aerospace sectors facilitates strong opportunities for Titomic to become a dominant player in the USD$4 trillion metals manufacturing industry for a green-tech future.”
Further, Dr Schwer stated; “I am honoured to accept the role of Chairman at Titomic and look forward to leading the Company to capitalise on its considerable opportunities and further add shareholder value. I believe Titomic’s industrial scale metal additive manufacturing and sustainable, green technology has tremendous commercial potential to take metal manufacturing industries into the future.”
Dr Schwer has a Dipl.-Ing in Aerospace Engineering and a PhD in System Modelling and Numerical Optimisation, both from the University of Stuttgart, and a Master of Science in System-Engineering from TU Delfi (The Netherlands).
Dr Schwer says he’s delighted to be joining the Board of a company that’s starting to make its presence felt globally, as demonstrated by the sale of two Titomic Kinetic Fusion® systems to a global defence manufacturer, as well as reaching agreements with companies of the calibre of Boeing, Airbus, and Thales.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200701005306/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom